Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 2

Status

Terminated 2

Sponsor Class

INDUSTRY 26OTHER 17NIH 6NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 138Cyclophosphamide 108Cisplatin 103Doxorubicin 99Vincristine 76Filgrastim 60Etoposide 58Paclitaxel 56Carboplatin 53Fluorouracil 51Methotrexate 49Dexamethasone 49Cytarabine 43Prednisone 42Leucovorin 40Granulocyte Colony-Stimulating Factor 34Docetaxel 34Radiation 31Specimen Handling 30Tamoxifen 27Daunorubicin 27Magnetic Resonance Spectroscopy 26Calcium Dobesilate 26Ifosfamide 25Mercaptopurine 24Gemcitabine 24Platinum 22Goserelin 221,2-diaminocyclohexaneplatinum II citrate 22Chemotherapy, Adjuvant 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × Gefitinib × Clear all
NCT00352079 2023-08-04

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Canadian Cancer Trials Group

Phase 3 Terminated
41 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00091156 2012-07-16

Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Terminated
598 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡